<DOC>
	<DOCNO>NCT00907205</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability SF1126 patient advance metastatic tumor assess dose limit toxicity ( DLTs ) define maximum tolerated dose give twice per week 4 week ultimately define recommend phase II dose .</brief_summary>
	<brief_title>A Dose Escalation Study SF1126 , PI3 Kinase ( PI3K ) Inhibitor , Given By Intravenous ( IV ) Infusion Patients With Solid Tumors</brief_title>
	<detailed_description>SF1126 conjugate contain vascular target pan-PI3K inhibitor selectively inhibit PI3K class I isoforms key member PI3K superfamily , include mTORC1/2 , DNA-PK , PLK-1 , CK2 , ATM PIM-1 . SF1126 design inhibit angiogenesis cell proliferation target bind specific integrins αγβ3 express surface new tumor vasculature within tumor compartment . In preclinical xenograft model SF1126 demonstrate broad activity single agent ; synergy commonly use chemotherapy agent , target agent , radiation ; show reverse resistance mediate PI3K/PTEN pathway .</detailed_description>
	<criteria>To qualify enrollment , follow criterion must meet : Written inform consent . At least 18 year old . Accrual limit patient tumor type opinion investigator know PTEN loss PI3 Kinase mutation potentially important biology cancer . Only patient histologically confirmation advanced solid malignant tumor refractory standard therapy standard therapy exists . Eastern Cooperative Oncology Group Performance Status 0 1 . Life expectancy &gt; = 12 week . Female subject eligible enter participate study : nonchildbearing potential , hysterectomy , bilateral oophorectomy ( ovariectomy ) , bilateral tubal ligation , postmenopausal childbearing potential negative serum pregnancy test screen agrees protection IUD , vasectomize partner , complete abstinence , double barrier contraception . male patient childbearing potential must agree use adequate contraception study . patient active therapy wellcontrolled diabetes define fast glucose &lt; 160mg/dL . Brain metastasis spinal cord compression , unless treatment complete least 4 week entry , stable without steroid treatment least 4 week . Inadequate bone marrow reserve demonstrate absolute neutrophil count &lt; 1.5 x 10^9/L platelet count &lt; 100 x 10^9/L ( posttransfusion ) hemoglobin &lt; 9 g/dL ( posttransfusion ) . Serum bilirubin &gt; = 1.2 time upper limit normal . An ALT AST level &gt; = 2.5 time upper limit normal . If document liver metastasis present , ALT AST level must still less 2.5 time upper limit normal . Serum creatinine &gt; 1.5 time upper limit normal creatinine clearance &lt; = 50mL/min calculated CockcroftGault equation . Evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac [ include life threaten arrhythmias ] , hepatic , renal disease . Unresolved toxicity ≥CTC Grade 2 previous anticancer therapy except alopecia ( applicable ) unless agree patient enter discussion Medical Monitor . QTc prolongation define QTc &gt; 450 m male &gt; 470ms female ( Fridericia ) 3 consecutive ECGs ; OR prior history cardiovascular disease include heart failure meet New York Hearth Association ( NYHA ) class III IV definition , OR history myocardial infarction/active ischemic heart disease within one year study entry ; OR uncontrolled dysrhythmias ; OR poorly control angina . Participation trial investigational agent within prior 30 day . Pregnant breastfeeding female . High volume peritoneal pleural effusion require tap frequently every 14 day . History malignancy except curatively excise carcinoma situ cervix , nonmelanomatous skin carcinoma superficial bladder cancer solid tumor curatively treat evidence disease &gt; = 5 year . Other case review possibly allow discuss approve Medical Monitor . Patients receive therapeutic dos Warfarin . Any concurrent condition investigator 's opinion make undesirable subject participate trial would jeopardize compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Metastatic Solid Tumors</keyword>
	<keyword>PI3K</keyword>
	<keyword>PI3K Inhibitors</keyword>
	<keyword>PI3 Kinase Inhibitors</keyword>
	<keyword>mTORC inhibitor</keyword>
	<keyword>mTORC1 inhibitor</keyword>
	<keyword>mTORC2 inhibitor</keyword>
	<keyword>vascular target</keyword>
	<keyword>conjugate</keyword>
</DOC>